{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-125359","form_type":"8-K","ticker":"ARTV","cik":"0001817241","company_name":"Artiva Biotherapeutics, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.799267+00:00","generated_at":"2026-05-30T02:08:24.852419+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Artiva Q3 2024 net loss $17.5M; cash $199.6M; AlloNK data expected H1 2025","bullets":["Net loss of $17.5M for Q3 2024 vs net income of $11.3M a year ago as collaboration revenue ended.","Cash, equivalents and investments $199.6M at Sep 30, 2024; expected to fund operations through end of 2026.","Completed upsized IPO in July 2024, gross proceeds $179.0M from 14.92M shares at $12.00.","First patient dosed in AlloNK IIT for autoimmune diseases; initial Phase 1/1b and IIT data due H1 2025.","Appointed Dr. Alison Moore to Board of Directors, bringing allogeneic cell therapy manufacturing expertise."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-125359","json":"https://secwatch.observer/filing/0000950170-24-125359.json","markdown":"https://secwatch.observer/filing/0000950170-24-125359.md","text":"https://secwatch.observer/filing/0000950170-24-125359.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817241/000095017024125359/0000950170-24-125359-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817241/000095017024125359/artv-20241112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:08:24.852419+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}